IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by ERBA Diagnostics, Inc. (“ERBA” or the “Company”) (NYSE MKT: ERB). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
If you purchased shares of ERBA during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at email@example.com.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
On November 16, 2015, ERBA announced it would delay filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 citing its continued “efforts to improve the effectiveness of its internal control over financial reporting.” Then on November 20, 2015, the Company announced that the Audit Committee of the Board of Directors had determined that the financial statements for the years ended December 31, 2013 and 2014 and for each of the interim periods ended March 31, 2015 and June 30, 2015 should no longer be relied upon. When the truth was revealed, shares dropped causing investors harm.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.